107 related articles for article (PubMed ID: 33455008)
1. Melanoma brain metastases: Biological basis and novel therapeutic strategies.
Phadke M; Ozgun A; Eroglu Z; Smalley KSM
Exp Dermatol; 2022 Jan; 31(1):31-42. PubMed ID: 33455008
[TBL] [Abstract][Full Text] [Related]
2. Improved survival of patients with melanoma brain metastases in the era of targeted BRAF and immune checkpoint therapies.
Sloot S; Chen YA; Zhao X; Weber JL; Benedict JJ; Mulé JJ; Smalley KS; Weber JS; Zager JS; Forsyth PA; Sondak VK; Gibney GT
Cancer; 2018 Jan; 124(2):297-305. PubMed ID: 29023643
[TBL] [Abstract][Full Text] [Related]
3. Improved Risk-Adjusted Survival for Melanoma Brain Metastases in the Era of Checkpoint Blockade Immunotherapies: Results from a National Cohort.
Iorgulescu JB; Harary M; Zogg CK; Ligon KL; Reardon DA; Hodi FS; Aizer AA; Smith TR
Cancer Immunol Res; 2018 Sep; 6(9):1039-1045. PubMed ID: 30002157
[TBL] [Abstract][Full Text] [Related]
4. Combination of immune-checkpoint inhibitors and targeted therapies for melanoma therapy: The more, the better?
Haist M; Stege H; Kuske M; Bauer J; Klumpp A; Grabbe S; Bros M
Cancer Metastasis Rev; 2023 Jun; 42(2):481-505. PubMed ID: 37022618
[TBL] [Abstract][Full Text] [Related]
5. MET receptor serves as a promising target in melanoma brain metastases.
Redmer T; Schumann E; Peters K; Weidemeier ME; Nowak S; Schroeder HWS; Vidal A; Radbruch H; Lehmann A; Kreuzer-Redmer S; Jürchott K; Radke J
Acta Neuropathol; 2024 Feb; 147(1):44. PubMed ID: 38386085
[TBL] [Abstract][Full Text] [Related]
6. Endothelial and tumor-intrinsic mechanisms of hepatic melanoma metastasis.
Wohlfeil SA; Géraud C
J Dtsch Dermatol Ges; 2024 Jan; 22(1):18-21. PubMed ID: 37884458
[TBL] [Abstract][Full Text] [Related]
7. Molecular Profiling Reveals Unique Immune and Metabolic Features of Melanoma Brain Metastases.
Fischer GM; Jalali A; Kircher DA; Lee WC; McQuade JL; Haydu LE; Joon AY; Reuben A; de Macedo MP; Carapeto FCL; Yang C; Srivastava A; Ambati CR; Sreekumar A; Hudgens CW; Knighton B; Deng W; Ferguson SD; Tawbi HA; Glitza IC; Gershenwald JE; Vashisht Gopal YN; Hwu P; Huse JT; Wargo JA; Futreal PA; Putluri N; Lazar AJ; DeBerardinis RJ; Marszalek JR; Zhang J; Holmen SL; Tetzlaff MT; Davies MA
Cancer Discov; 2019 May; 9(5):628-645. PubMed ID: 30787016
[TBL] [Abstract][Full Text] [Related]
8. Metastatic Melanoma Treatment in Special Populations.
Miceli M; Boatwright C; Mehnert JM
Cancer J; 2024 Mar-Apr 01; 30(2):71-78. PubMed ID: 38527259
[TBL] [Abstract][Full Text] [Related]
9. Vitreous metastasis from cutaneous melanoma while on checkpoint inhibitors.
Catapano TM; Bansal R; Shields CL
Asia Pac J Ophthalmol (Phila); 2024; 13(2):100050. PubMed ID: 38492668
[No Abstract] [Full Text] [Related]
10. Melanoma Brain Metastasis: Biology and Therapeutic Advances.
Hasanov M; Acikgoz Y; Davies MA
Hematol Oncol Clin North Am; 2024 Jun; ():. PubMed ID: 38845301
[TBL] [Abstract][Full Text] [Related]
11. Immune Checkpoint Blockade - How Does It Work in Brain Metastases?
Lorger M; Andreou T; Fife C; James F
Front Mol Neurosci; 2019; 12():282. PubMed ID: 31824260
[TBL] [Abstract][Full Text] [Related]
12. Proteogenomic analysis of melanoma brain metastases from distinct anatomical sites identifies pathways of metastatic progression.
Taylor EM; Byrum SD; Edmondson JL; Wardell CP; Griffin BG; Shalin SC; Gokden M; Makhoul I; Tackett AJ; Rodriguez A
Acta Neuropathol Commun; 2020 Sep; 8(1):157. PubMed ID: 32891176
[TBL] [Abstract][Full Text] [Related]
13. A General Approach to Patients Presenting With Locally Advanced or Distant Metastatic Disease.
Smithy JW; Chapman PB
Cancer J; 2024 Mar-Apr 01; 30(2):48-53. PubMed ID: 38527257
[TBL] [Abstract][Full Text] [Related]
14. Immunomodulatory Drugs in Melanoma Brain Metastases.
Fernandes GNC
Discoveries (Craiova); 2019 Jun; 7(2):e93. PubMed ID: 32309611
[TBL] [Abstract][Full Text] [Related]
15. Symptomatic brain metastases in melanoma.
Knox A; Wang T; Shackleton M; Ameratunga M
Exp Dermatol; 2024 Apr; 33(4):e15075. PubMed ID: 38610093
[TBL] [Abstract][Full Text] [Related]
16. Multi-omic profiling reveals discrepant immunogenic properties and a unique tumor microenvironment among melanoma brain metastases.
In GK; Ribeiro JR; Yin J; Xiu J; Bustos MA; Ito F; Chow F; Zada G; Hwang L; Salama AKS; Park SJ; Moser JC; Darabi S; Domingo-Musibay E; Ascierto ML; Margolin K; Lutzky J; Gibney GT; Atkins MB; Izar B; Hoon DSB; VanderWalde AM
NPJ Precis Oncol; 2023 Nov; 7(1):120. PubMed ID: 37964004
[TBL] [Abstract][Full Text] [Related]
17. Identification of dynamic microbiota signatures in patients with melanoma receiving ICIs: opportunities and challenges.
Maleki Vareki S; Davar D
Nat Rev Clin Oncol; 2024 Jun; 21(6):405-406. PubMed ID: 38509333
[No Abstract] [Full Text] [Related]
18. Preclinical models to understand the biology and to discover new targets in brain metastases.
Kindt N; Kotecki N; Awada A
Curr Opin Oncol; 2023 Sep; 35(5):436-440. PubMed ID: 37551950
[TBL] [Abstract][Full Text] [Related]
19. Identification of Epigenetically Regulated Genes Distinguishing Intracranial from Extracranial Melanoma Metastases.
Westphal D; Meinhardt M; Grützmann K; Schöne L; Steininger J; Neuhaus LT; Wiegel M; Schrimpf D; Aust DE; Schröck E; Baretton GB; Beissert S; Juratli TA; Schackert GG; Gravemeyer J; Becker JC; von Deimling A; Koelsche C; Klink B; Meier F; Schulz A; Muders MH; Seifert M
J Invest Dermatol; 2023 Jul; 143(7):1233-1245.e17. PubMed ID: 36716920
[TBL] [Abstract][Full Text] [Related]
20. Efficacy and Safety of Intrathecal Pemetrexed Combined With Dexamethasone for Treating Tyrosine Kinase Inhibitor-Failed Leptomeningeal Metastases From EGFR-Mutant NSCLC-a Prospective, Open-Label, Single-Arm Phase 1/2 Clinical Trial (Unique Identifier: ChiCTR1800016615).
Fan C; Zhao Q; Li L; Shen W; Du Y; Teng C; Gao F; Song X; Jiang Q; Huang D; Jin Y; Lv Y; Wei L; Shi T; Zhao X; Gao N; Jiang Z; Xin T
J Thorac Oncol; 2021 Aug; 16(8):1359-1368. PubMed ID: 33989780
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
